Signaturefd LLC Grows Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Signaturefd LLC lifted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 13.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 686 shares of the biotechnology company’s stock after purchasing an additional 80 shares during the period. Signaturefd LLC’s holdings in Ascendis Pharma A/S were worth $102,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of ASND. Price T Rowe Associates Inc. MD grew its stake in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after acquiring an additional 336,976 shares in the last quarter. Acadian Asset Management LLC grew its stake in Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after acquiring an additional 234,446 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares in the last quarter. Fred Alger Management LLC grew its stake in Ascendis Pharma A/S by 65.0% during the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after acquiring an additional 120,952 shares in the last quarter. Finally, Tri Locum Partners LP grew its stake in Ascendis Pharma A/S by 102.1% during the 2nd quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after acquiring an additional 115,092 shares in the last quarter.

Ascendis Pharma A/S Stock Down 0.7 %

Ascendis Pharma A/S stock opened at $129.44 on Tuesday. The firm has a market cap of $7.54 billion, a PE ratio of -13.47 and a beta of 0.64. Ascendis Pharma A/S has a 52-week low of $86.54 and a 52-week high of $161.00. The company’s 50 day moving average is $134.56 and its two-hundred day moving average is $134.11.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, equities research analysts anticipate that Ascendis Pharma A/S will post -7.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ASND. Bank of America increased their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $195.92.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.